Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
JCO Precision Oncology|March 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung CancerPetros Christopoulos, Michal Harel, Kimberly McGregor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyChrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
Journal of Translational Medicine|November 17, 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 13, 2021
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022Chrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2024
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024Chrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologySusan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
JCO Precision Oncology|March 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung CancerPetros Christopoulos, Michal Harel, Kimberly McGregor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyChrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
Journal of Translational Medicine|November 17, 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 13, 2021
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022Chrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2024
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024Chrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologySusan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Pageof 21